PGT-A or PGT-M After a Genetic Finding in a Prior Pregnancy?

Ask for the original diagnostic laboratory report, sampling details, any prenatal ultrasound findings and documentation of what the result means. Some results come from screening tests and were not confirmed diagnostically; that distinction is critical. A genetic counsellor can clarify whether a particular result is likely de novo, inherited or uncertain. If there was pregnancy loss, a pathology or pregnancy-tissue report may be relevant, but not every test accurately establishes the cause of the loss.

PGT-M is designed around a specific known monogenic condition, usually requiring confirmation of the familial variant and laboratory preparation. PGT-SR relates to selected structural chromosome rearrangements after appropriate parental testing. PGT-A assesses chromosome copy-number patterns in biopsied embryo cells, which is not equivalent to testing for a known family mutation. PGT testing is performed on embryos created through IVF at a specialist embryology and genetics facility. The test can have limitations, inconclusive results and costs, and may not be the best choice for every couple.

Options may include reproductive planning without IVF, targeted prenatal diagnosis in a later pregnancy, donor gametes in selected settings or not pursuing testing, depending on personal values and medical context. Embryo biopsy does not remove every genetic or pregnancy risk, and routine prenatal care remains important even when PGT is used. Ask whether confirmatory prenatal testing would be advised and how counselling will explain mosaic, no-result or uncertain findings. A good consultation presents choices instead of presenting IVF as the only ethical response to a difficult previous experience.

For some PGT-M cases, designing and validating the laboratory test may require family samples and substantial preparation before eggs are retrieved. Ask which variant is being targeted, whether the laboratory has accepted the case, how embryo biopsy and freezing would be coordinated, and who signs off results. Clarify what happens if no embryos are suitable or if a result is inconclusive. The decision to stimulate ovaries should not outrun the genetics workup merely because an appointment slot is available.

HomeIVF is a doctor-led fertility and IVF care model designed to reduce unnecessary trips, not a home genetics laboratory. Medical history, family documents and some counselling may be reviewed remotely when suitably provided. Any prescribed blood collection at home depends on verified collection capability, consent and specimen handling. If IVF is appropriate, ovarian monitoring includes facility scans, with retrieval, fertilisation, embryo biopsy, freezing and transfer performed in properly equipped clinics and laboratories. A clinical geneticist and reproductive specialist should each take responsibility for their parts of the decision; neither an online tool nor a coordinator can replace informed genetic counselling.

A robust plan names the clinical geneticist, the fertility specialist and the laboratory responsible for the assay. Ask which consent forms are required and whether both partners must attend a particular appointment. The team should describe how results will be communicated, what a no-result embryo report means, and which confirmatory pregnancy testing may later be discussed. Written coordination matters because laboratory terminology can be misunderstood when it passes through several people. A coordinator can organise the sequence but must not reinterpret genetic variants independently.

Ask whether the genetic finding has been confirmed and whether the proposed test is technically feasible for the family. Request an explanation of no-result embryos, residual risk, prenatal alternatives, storage and what happens if no embryos are suitable for transfer. Clarify whether consent, payment or laboratory setup is needed before starting stimulation. Genetic counselling should use plain language and include family and reproductive values, not only laboratory success claims. A precise written plan helps avoid unnecessary procedures when the test being purchased cannot answer the family’s actual question.

Counselling, confirmation of family variants, creation or validation of an assay, IVF medicines, retrieval, embryo culture, biopsy, testing, freezing, storage and eventual transfer may be separate charges. A laboratory quote may cover only a portion of this pathway. Request fees for inconclusive findings and for a cycle that produces no embryos to test. Patients should know which charges are clinical necessities and which are optional choices. No test should be bought to solve an unrelated genetic question merely because the package lists it.

Genetic test results can affect embryo decisions and family planning, so interpretation belongs with qualified clinicians. Do not discard or transfer embryos based solely on an informal online explanation. The team should discuss uncertain and no-result findings, prenatal care and the possibility of having no embryos suitable for transfer. Any ovarian stimulation still requires ordinary medical monitoring and emergency instructions. Remote counselling does not change the need for a safe procedure facility.

Some genetic results have implications beyond the two people considering IVF. A genetic counsellor can explain whether relatives might benefit from testing and how privacy and consent should be respected. Do not circulate raw reports in family messaging groups or assume that an uncertain variant predicts disease. The correct interpretation should come from the laboratory and clinical genetics team, and the family should retain control over sensitive information.